Real‐world experience on the tolerability and safety of emicizumab prophylaxis in paediatric patients with severe haemophilia A with and without FVIII inhibitors

医学 耐受性 不利影响 血友病 药物警戒 恶心 儿科 队列 上市后监督 内科学
作者
Eman Hassan,Lancashire Jonathan,Motwani Jayashree
出处
期刊:Haemophilia [Wiley]
卷期号:27 (6) 被引量:16
标识
DOI:10.1111/hae.14432
摘要

Abstract Background Emicizumab is a bispecific monoclonal antibody that bridges activated factor (F) IX and FX, and maintains haemostasis in patients with haemophilia A (PwHA). As a novel agent, many questions remain unanswered about the loss of emicizumab efficacy due to anti‐drug antibody (ADA) development, the incidence of inhibitor recurrence in previously tolerized patients, and the risk of de novo inhibitor development. Aim To present real‐world experience regarding tolerability, side effects, and outcomes of adverse events of emicizumab prophylaxis in paediatric PwHA. Methods Data on tolerability, compliance, adverse events, and laboratory results of paediatric patients receiving emicizumab prophylaxis, treated at the Haemophilia Comprehensive Care Centre, at Birmingham Children's Hospital between March 2018 and June 2021, were collected. Results Our results showed that out of 52 patients, four experienced minor adverse events, two developed headaches, one developed abdominal pain and nausea, and one developed injection site reactions. Moreover, four patients experienced major adverse events, including severe headaches, major bleeding events, development of ADAs, and recurrence of inhibitors. Emicizumab prophylaxis was discontinued in three patients (5.7% of the cohort) due to adverse events. In addition, emicizumab was discontinued in one patient because of poor compliance. No adverse events were reported in previously untreated/minimally treated patients, represented by four patients in our cohort. Conclusions The real‐world experience of emicizumab prophylaxis in our cohort showed that emicizumab was safe and well tolerated in paediatric PwHA with and without inhibitors. Long‐term assessment is crucial to monitor major adverse events, recurrence of inhibitors, and development of ADAs.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
浅辰完成签到,获得积分10
1秒前
大气萤完成签到,获得积分20
2秒前
2秒前
我ppp完成签到 ,获得积分10
2秒前
3秒前
易燃物品完成签到,获得积分10
3秒前
Hello应助Ther采纳,获得10
5秒前
CherylZhao完成签到,获得积分10
6秒前
Galato发布了新的文献求助10
7秒前
颜愫完成签到,获得积分10
7秒前
安详向日葵完成签到 ,获得积分10
8秒前
拼搏的白云完成签到,获得积分10
8秒前
852应助hhh采纳,获得10
8秒前
李白白白完成签到,获得积分10
8秒前
王手完成签到,获得积分10
8秒前
9秒前
一人完成签到,获得积分10
10秒前
do0完成签到,获得积分10
11秒前
yar应助xlz110采纳,获得10
11秒前
NexusExplorer应助落寞凌波采纳,获得10
13秒前
量子星尘发布了新的文献求助10
16秒前
123完成签到 ,获得积分10
16秒前
哈哈呵完成签到,获得积分10
16秒前
16秒前
Rylee完成签到,获得积分10
16秒前
Jiro完成签到,获得积分10
18秒前
我ppp发布了新的文献求助60
19秒前
20秒前
纳米酶催化完成签到,获得积分10
21秒前
21秒前
John完成签到,获得积分10
21秒前
李小强完成签到,获得积分10
22秒前
23秒前
26秒前
落寞凌波发布了新的文献求助10
26秒前
26秒前
27秒前
健壮的尔烟完成签到,获得积分10
27秒前
三三完成签到 ,获得积分10
27秒前
白betty完成签到,获得积分10
29秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Handbook of Industrial Diamonds.Vol2 1100
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038368
求助须知:如何正确求助?哪些是违规求助? 3576068
关于积分的说明 11374313
捐赠科研通 3305780
什么是DOI,文献DOI怎么找? 1819322
邀请新用户注册赠送积分活动 892672
科研通“疑难数据库(出版商)”最低求助积分说明 815029